Federica Fogacci: Lp(a) Doesn’t Simply Add Risk – It Reframes Risk
Federica Fogacci, Editorial Board member and Social Media Editor at Atherosclerosis, shared on LinkedIn:
“Lp(a) doesn’t simply add risk. It reframes risk. For patients, it can turn a test result into a long-term insight—and, at times, a family story.
That’s why “should we test?” is no longer the real question. The real question is whether we can implement Lp(a) testing in a way that is clear, useful, and supportive. Elevated Lp(a) is common and consistently linked to major cardiovascular outcomes, yet measurement is still far from routine. In our new Journal of Clinical Lipidology editorial (with Arrigo F.G. Cicero and Peter Libby), we argue it’s no longer a dilemma. It’s a mandate.
But a mandate without a patient-centred pathway is just a number on a report. If we want Lp(a) testing to matter, we need to make the experience work for real people: communication that informs without alarming, a clear “what next,” and support for family conversations—including cascade screening when appropriate.
This is also where alignment is possible. Clinicians can normalise when and how to measure Lp(a) and how to frame results. Patient organisations can help ensure the message lands in a way that empowers rather than overwhelms. And researchers and industry can translate this momentum into scalable pathways—and, ultimately, better options for care.”
Title: Lipoprotein(a)—To test or not to test, not a dilemma but a mandate
Authors: Federica Fogacci, Peter Libby, Arrigo Francesco Giuseppe Cicero
Stay updated with Hemostasis Today.
-
Jun 1, 2026, 18:51Francesco Giurazza: New Publication on Glubran-2 in Acute Bleeding Patients with Coagulopathies
-
Jun 1, 2026, 18:50Donald Arnold is the Recipient of the Roberts Award – ISTH
-
Jun 1, 2026, 18:49Amirreza Jabbaripour Sarmadian: My First Paper as Corresponding Author on Upper Extremity DVT Following COVID-19 Vaccination
-
Jun 1, 2026, 18:49James P. Crowley: How Combining Vitamin D analogs with Chemotherapy Impacts Survival Outcomes
-
Jun 1, 2026, 18:42Debojyoti Chakraborty: Small But Meaningful Steps Toward A Gene Editing Trial For Sickle Cell Disease In India
-
Jun 1, 2026, 17:14Tiffany Gacel: What an Incredible Day With NBCA and The Red Bus Tour at Memorial at Gulfport?
-
Jun 1, 2026, 17:12Marie-Claire Kofi: Poster Highlights the Process of Establishing the Sickle Cell Transitions Policy Lab
-
Jun 1, 2026, 17:00Azusa Nagao: Organizing the Symposium on Women and Bleeding Disorders at JSTH Annual Meeting
-
Jun 1, 2026, 16:57Kuljeet Kaur: Approach to Anemia – More Than Just a Low Hemoglobin